keyword
https://read.qxmd.com/read/38633125/poor-outcomes-for-trial-ineligible-patients-receiving-polatuzumab-for-relapsed-refractory-diffuse-large-b-cell-lymphoma-in-routine-care-an-australian-lymphoma-and-related-diseases-registry-project
#1
JOURNAL ARTICLE
Briony Shaw, Eliza Chung, Cameron Wellard, Edward Yoo, Rory Bennett, Callum Birks, Anna Johnston, Chan Y Cheah, Nada Hamad, Jock Simpson, Allison Barraclough, Matthew Ku, Nicholas Viiala, Sumita Ratnasingam, Tasman Armytage, Tara Cochrane, Geoffrey Chong, Denise Lee, Kate Manos, Colm Keane, Stephanie Wallwork, Stephen Opat, Eliza A Hawkes
Polatuzumab vedotin (Pola) is an approved therapy in combination with rituximab and bendamustine for relapsed or refractory diffuse large B-cell lymphoma (RR-DLBCL) based on positive results of the landmark phase II randomised G029365 trial. However, trial results for many approved novel therapies in RR-DLBCL have not been replicated in routine care cohorts, as RR-DLBCL patient populations are heterogeneous and trial eligibility is increasingly restrictive. We evaluated outcomes from pola ± bendamustine and rituximab in patients with RR-DLBCL enrolled in a compassionate access program with no alternative treatment options identified via the Australasian Lymphoma and Related Diseases Registry according to their eligibility for the original phase II published study...
April 2024: EJHaem
https://read.qxmd.com/read/38633122/nationwide-implementation-of-lenalidomide-maintenance-in-multiple-myeloma-a-retrospective-real-world-study
#2
JOURNAL ARTICLE
Mads Harsløf, Iman Chanchiri, Trine Silkjær, Ulf Christian Frølund, Elena Manuela Teodorescu, Kristina Buchardi Nielsen, Per Ishøy Nielsen, Per Trøllund Pedersen, Katrine Fladeland Iversen, Thomas Lund, Kirsten Grønbæk, Sigrun Thorsteinsdottir, Annette Vangsted, Agoston Gyula Szabo
Lenalidomide maintenance (LM) has shown benefit in progression-free survival (PFS) and overall survival (OS) in clinical trials. LM is the recommended standard of care in patients with newly diagnosed multiple myeloma (MM) after high-dose melphalan and autologous stem cell transplantation (HDM-ASCT). In Denmark, LM has been approved and publicly funded for all patients treated with HDM-ASCT since June 2019. Patients with newly diagnosed MM treated with their first HDM-ASCT between June 2019 and March 2022 were included and followed until data cut-off in June 2023...
April 2024: EJHaem
https://read.qxmd.com/read/38628818/does-the-dose-of-standard-adjuvant-chemotherapy-affect-the-triple-negative-breast-cancer-benefit-from-extended-capecitabine-metronomic-therapy-an-exploratory-analysis-of-the-sysucc-001-trial
#3
Ying Chen, Wen-Xia Li, Jia-Hua Wu, Geng-Hang Chen, Chun-Min Yang, Hai Lu, Xi Wang, Shu-Sen Wang, Heng Huang, Li Cai, Li Zhao, Rou-Jun Peng, Ying Lin, Jun Tang, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, An-Qin Zhang, Fei Xu, Xi-Wen Bi, Jia-Jia Huang, Ji-Bin Li, Dan-Mei Pang, Cong Xue, Yan-Xia Shi, Zhen-Yu He, Huan-Xin Lin, Xin An, Wen Xia, Ye Cao, Ying Guo, Ruo-Xi Hong, Kui-Kui Jiang, Yong-Yi Zhong, Ge Zhang, Piyawan Tienchaiananda, Masahiro Oikawa, Zhong-Yu Yuan, Qian-Jun Chen
PURPOSE: Results from studies of extended capecitabine after the standard adjuvant chemotherapy in early stage triple-negative breast cancer (TNBC) were inconsistent, and only low-dose capecitabine from the SYSUCC-001 trial improved disease-free survival (DFS). Adjustment of the conventional adjuvant chemotherapy doses affect the prognosis and may affect the efficacy of subsequent treatments. This study investigated whether the survival benefit of the SYSUCC-001 trial was affected by dose adjustment of the standard adjuvant chemotherapy or not...
2024: Breast Cancer: Targets and Therapy
https://read.qxmd.com/read/38619575/safety-and-feasibility-of-early-discharge-after-transcatheter-aortic-valve-implantation-with-acurate-neo-the-polestar-trial
#4
JOURNAL ARTICLE
Joris F Ooms, Kristoff Cornelis, Harindra C Wijeysundera, Bert Vandeloo, Jan Van Der Heyden, Jan Kovac, David Wood, Albert Chan, Joanna Wykyrzykowska, Liesbeth Rosseel, Michael Cunnington, Frank van der Kley, Benno Rensing, Michiel Voskuil, David Hildick-Smith, Nicolas M Van Mieghem
BACKGROUND: Transcatheter aortic valve implantation (TAVI) serves a growing range of patients with severe aortic stenosis (AS). TAVI has evolved to a streamlined procedure minimizing length of hospital stay. AIMS: To evaluate the safety and efficacy of an early discharge (ED) strategy after TAVI. METHODS: We performed an international, multi-center, prospective observational single-arm study in AS patients undergoing TAVI with the ACURATE valve platform...
April 15, 2024: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
https://read.qxmd.com/read/38614009/circulating-tumour-dna-based-molecular-residual-disease-detection-in-resectable-cancers-a-systematic-review-and-meta-analysis
#5
JOURNAL ARTICLE
Jiachun Zheng, Chuling Qin, Qianxi Wang, Dongbo Tian, Zisheng Chen
BACKGROUND: Circulating tumour DNA (ctDNA)-based molecular residual disease (MRD) detection technology has been widely used for recurrence evaluation, but there is no agreement on the efficacy of assessing recurrence and overall survival (OS) prognosis, as well as the sensitivity and specificity of landmark detection and longitudinal detection. METHODS: We systematically searched Pubmed, Embase, Cochrane, and Scopus for prospective studies or randomized controlled trials that collected blood samples prospectively...
April 12, 2024: EBioMedicine
https://read.qxmd.com/read/38612688/targeting-her2-in-gastroesophageal-adenocarcinoma-molecular-features-and-updates-in-clinical-practice
#6
REVIEW
Maria Bonomi, Daniele Spada, Gian Luca Baiocchi, Andrea Celotti, Matteo Brighenti, Giulia Grizzi
Gastroesophageal adenocarcinoma (GEA) is one of the principal causes of death related to cancer globally. Human epidermal growth factor receptor 2 (HER2) is a tyrosine kinase receptor which is found to be overexpressed or amplified in approximately 20% of GEA cases. In GEA, the identification of HER2-positive status is crucial to activate a specific anti-HER2 targeted therapy. The landmark ToGA trial demonstrated the superiority of adding trastuzumab to platinum-based chemotherapy, becoming the first-line standard of treatment...
March 30, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38610878/pharmacological-and-benefit-risk-profile-of-once-weekly-basal-insulin-administration-icodec-addressing-patients-unmet-needs-and-exploring-future-applications
#7
REVIEW
Ylenia Ingrasciotta, Giacomo Vitturi, Gianluca Trifirò
Diabetes mellitus (DM) is a chronic metabolic disease affecting over 500 million people worldwide, which leads to severe complications and to millions of deaths yearly. When therapeutic goals are not reached with diet, physical activity, or non-insulin drugs, starting/adding insulin treatment is recommended by international guidelines. A novel recombinant insulin is icodec, a once-weekly insulin that successfully completed phase III trials and that has recently obtained the marketing authorization approval from the European Medicines Agency...
April 5, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38610667/landmark-evolutions-in-time-and-indication-for-cardiac-resynchronization-therapy-results-from-a-multicenter-retrospective-registry
#8
JOURNAL ARTICLE
Jeroen Bijnens, Sander Trenson, Gabor Voros, Pieter Martens, Sebastian Ingelaere, Pascal Betschart, Jens-Uwe Voigt, Matthias Dupont, Alexander Breitenstein, Jan Steffel, Rik Willems, Frank Ruschitzka, Wilfried Mullens, Stephan Winnik, Bert Vandenberk
Background: Cardiac resynchronization therapy (CRT) has evolved into an established therapy for patients with chronic heart failure and a wide QRS complex. Data on long-term outcomes over time are scarce and the criteria for implantation remain a subject of investigation. Methods: An international, multicenter, retrospective registry includes 2275 patients who received CRT between 30 November 2000 and 31 December 2019, with a mean follow-up of 3.6 ± 2.7 years. Four time periods were defined, based on landmark trials and guidelines...
March 25, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38607923/protocol-to-quantify-bird-nest-morphology-via-image-analyses-using-linear-measurements-and-geometric-landmarks
#9
JOURNAL ARTICLE
Benjamin Whittaker, Andrés Camacho-Alpízar, Lauren Guillette
Here, we present a protocol to quantify bird nest morphology via image analyses. We describe steps for collecting linear size measurements, placing geometric landmarks, and undertaking generalized Procrustes analysis to extract coordinate data. This protocol was designed to measure within- and among-individual variation in the morphology of dome nests built by captive zebra finches using coconut fiber in a laboratory environment. For complete details on the use and execution of this protocol, please refer to Whittaker et al...
April 11, 2024: STAR protocols
https://read.qxmd.com/read/38606650/association-of-device-detected-atrial-and-ventricular-tachyarrhythmia-with-adverse-events-in-patients-with-an-implantable-cardioverter-defibrillator
#10
JOURNAL ARTICLE
Hassan Abbas, Arwa Younis, Ilan Goldenberg, Scott McNitt, Mehmet K Aktas, Chadi Tabaja, Amole Ojo
INTRODUCTION: Heart failure patients with a history of atrial fibrillation (AF) and ventricular tachycardia/ventricular fibrillation (VT/VF) are known to have worse outcomes. However, there are limited data on the temporal relationship between development of these arrhythmias and the risk of subsequent congestive heart failure (CHF) exacerbation and death. METHODS: The study cohort comprised 5511 patients implanted with an implantable cardioverter-defibrillator (ICD) in landmark clinical trials (MADIT-II, MADIT-RISK, MADIT-CRT, MADIT-RIT, and RAID) who were in sinus rhythm at enrollment...
April 12, 2024: Journal of Cardiovascular Electrophysiology
https://read.qxmd.com/read/38602016/the-need-for-more-pragmatic-trials-in-glaucoma-research
#11
JOURNAL ARTICLE
Mayara Fernanda Pacovska, Camila Lisandra Dantas de Amorim-Cabral, Eloisa Gomes do Rosário Monteiro Teixeira, Niro Kasahara
AIM: There have been a number of clinical trials in glaucoma research published in the past two decades. Most of these trials were designed to evaluate very specific issues in selected populations placing them in the explanatory end of the pragmatic-explanatory continuum. The purpose of this study was to assess the level of pragmatism of published randomized controlled trials in glaucoma. METHODS: A PubMed search using 'glaucoma' from 1995 to 2022 and randomized controlled trial (RCT) article type was done...
April 11, 2024: European Journal of Ophthalmology
https://read.qxmd.com/read/38599778/balanced-on-the-biggest-wave-nirsevimab-for-newborns
#12
JOURNAL ARTICLE
Christopher McPherson, Christine R Lockowitz, Jason G Newland
Respiratory syncytial virus (RSV) is the leading cause of hospitalization in infancy in the United States. Nearly all infants are infected by 2 years of age, with bronchiolitis requiring hospitalization often occurring in previously healthy children and long-term consequences of severe disease including delayed speech development and asthma. Incomplete passage of maternal immunity and a high degree of genetic variability within the virus contribute to morbidity and have also prevented successful neonatal vaccine development...
April 1, 2024: Neonatal Network: NN
https://read.qxmd.com/read/38598710/myeloablative-vs-non-myeloablative-consolidation-for-primary-central-nervous-system-lymphoma-results-of-alliance-51101
#13
JOURNAL ARTICLE
Tracy T Batchelor, Sharmila Giri, Amy S Ruppert, Susan Geyer, Scott E Smith, Nimish Mohile, Lode J Swinnen, Jonathan W Friedberg, Brad S Kahl, Nancy L Bartlett, Eric D Hsi, Bruce David Cheson, Nina D Wagner-Johnston, Lakshmi Nayak, John P Leonard, James Louis Rubenstein
While it is evident that standard dose whole brain radiotherapy as consolidation is associated with significant neurotoxicity, the optimal consolidative strategy for primary central nervous system lymphoma (PCNSL) is not defined. We performed a randomized phase 2 clinical trial via the U.S. Alliance cancer cooperative group to compare myeloablative consolidation supported by autologous stem cell transplantation with non-myeloablative consolidation after induction therapy for PCNSL. This is the first randomized trial to be initiated that eliminates whole brain radiotherapy as a consolidative approach in newly-diagnosed PCNSL...
April 10, 2024: Blood Advances
https://read.qxmd.com/read/38592711/hemophilia-b-and-gene-therapy-a-new-chapter-with-etranacogene-dezaparvovec
#14
REVIEW
Xavier M Anguela, Katherine A High
The US Food and Drug Administration (FDA)'s authorization of etranacogene dezaparvovec (Hemgenix) is a significant milestone, constituting not only the first FDA approval of a gene therapy for hemophilia but also the first approval of a liver-targeted adeno-associated virus vector gene therapy. This review summarizes the nonclinical studies and clinical development that supported regulatory clearance. Similar to other gene therapies for single gene disorders, both the short-term safety and the phenotypic improvement were unequivocal, justifying the modest-sized safety and efficacy database, which included 57 participants across the phase 2b (3 participants) and phase 3 (54 participants) studies...
April 9, 2024: Blood Advances
https://read.qxmd.com/read/38590650/prospective-evaluation-of-patient-reported-outcomes-of-invisible-ink-tattoos-for-the-delivery-of-external-beam-radiation-therapy-the-prefer-trial
#15
JOURNAL ARTICLE
Camille Hardy-Abeloos, Daniel Gorovets, Aurora Lewis, Wenyan Ji, Alicia Lozano, Chih Chun Tung, Francis Yu, Alexandra Hanlon, Haibo Lin, Anh Kha, Yoshiya Yamada, Rafi Kabarriti, Stanislav Lazarev, Shaakir Hasan, Arpit M Chhabra, Charles B Simone, J Isabelle Choi
INTRODUCTION: Invisible ink tattoos (IITs) avoid cosmetic permanence of visible ink tattoos (VITs) while serving as more reliable landmarks for radiation setup than tattooless setups. This trial evaluated patient-reported preference and feasibility of IIT implementation. METHODS AND MATERIALS: In an IRB-approved, single institution, prospective trial, patients receiving proton therapy underwent IIT-based treatment setup. A survey tool assessed patient preference on tattoos using a Likert scale...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38587598/immune-checkpoint-inhibitors-in-geriatric-oncology
#16
REVIEW
Sarah L Cook, Md Al Amin, Shahla Bari, Pradeep J Poonnen, Mustafa Khasraw, Margaret O Johnson
PURPOSE OF REVIEW: This manuscript will update prior reviews of immune checkpoint inhibitors (ICIs) in light of basic science, translational, and clinical discoveries in the field of cancer immunology and aging. RECENT FINDINGS: ICIs have led to significant advancements in the treatment of cancer. Landmark trials of ICIs have cited the efficacy and toxicity experienced by older patients, but most trials are not specifically designed to address outcomes in older patients...
April 8, 2024: Current Oncology Reports
https://read.qxmd.com/read/38585681/direct-oral-anticoagulant-use-early-after-cardiac-surgery-a-retrospective-cohort-study
#17
JOURNAL ARTICLE
Jung-Jin Wu, Jessie Jiang, Jian Ye, Ricky D Turgeon, Erica H Z Wang
BACKGROUND: There is limited literature guiding the prescribing of direct oral anticoagulants (DOACs) early after cardiac surgery as this population has been excluded from landmark randomized controlled trials. This study aims to determine the rate of in-hospital DOAC use compared with warfarin early after cardiac surgery, evaluate factors associated with DOAC use, determine difference in postoperative length of stay, and characterize bleeding events. METHODS: A retrospective cohort study was conducted in adult patients with indications for anticoagulation and receiving either a DOAC or warfarin after cardiac surgery during their index hospitalization...
February 2024: CJC open
https://read.qxmd.com/read/38583107/trends-in-oral-anticoagulant-use-and-individual-expenditures-across-the-united-states-from-2014-to-2020
#18
JOURNAL ARTICLE
Omar S Alkhezi, Leo F Buckley, John Fanikos
BACKGROUND: Landmark clinical trials have expended the indications for the direct oral anticoagulants (DOACs), but contemporary data on usage and expenditure patterns are lacking. OBJECTIVE: This study aimed to assess annual trends in oral anticoagulant (OAC) utilization and expenditure across the United States (US) from 2014 to 2020. METHODS: We utilized the Medical Expenditure Panel Survey (MEPS) to study the trends of use and expenditures of warfarin, dabigatran, rivaroxaban, apixaban, and edoxaban between 2014 and 2020 in the US...
April 7, 2024: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/38582301/landmark-use-by-ghost-crab-ocypode-quadrata-during-wayfinding-in-a-complex-maze
#19
JOURNAL ARTICLE
Trent Robinson
Species of crab have been shown to spatially track and navigate to consequential. locations through different processes, such as path integration and landmark orienting. Few investigations examine their ability to wayfind in complex environments, like. mazes, with multiple intersections and how they may utilize specific features to benefit. this process. Spatial learning potentially would lend a fitness advantage to animals. living in complicated habitats, and ghost crab (Ocypode quadrata) is a semiterrestrial...
April 4, 2024: Behavioural Processes
https://read.qxmd.com/read/38578141/the-first-mash-drug-therapy-on-the-horizon-current-perspectives-of-resmetirom
#20
REVIEW
Salvatore Petta, Giovanni Targher, Stefano Romeo, Utpal B Pajvani, Ming-Hua Zheng, Alessio Aghemo, Luca V C Valenti
The rising prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) poses a significant global health challenge, affecting over 30% of adults worldwide. MASLD is linked to increased mortality rates and substantial healthcare costs, primarily driven by its progression to metabolic dysfunction-associated steatohepatitis (MASH), which can lead to severe liver complications including cirrhosis and hepatocellular carcinoma. Despite its growing burden, effective pharmacotherapy for MASLD/MASH has been lacking until the recent conditional approval of resmetirom by the FDA...
April 5, 2024: Liver International: Official Journal of the International Association for the Study of the Liver
keyword
keyword
11836
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.